文献速递脑血管病认知障碍与痴呆

多组学分析支持组织蛋白酶B作为白质高信号与认知的保护因子

Multiomics Profiling Supports Cathepsin B as a Protective Factor in White Matter Hyperintensities and Cognition
RSS 订阅 · Stroke

本研究通过四阶段蛋白质基因组学分析,在UK Biobank参与者中探索循环蛋白与白质高信号(WMH)的因果关系。结果显示血浆CTSB较高与WMH体积较低相关,孟德尔随机化方向一致,且CTSB在病灶中表达下调,并预测更好的认知表现。CTSB可能是脑小血管病的治疗靶点。

要点

  • 血浆CTSB较高与WMH体积较低相关(β=-0.09)。
  • 孟德尔随机化支持CTSB对WMH的保护性因果效应。
  • CTSB在WMH病灶中星形胶质细胞和少突胶质细胞下调。

核心结论

  • 多模态蛋白质基因组学证据提名CTSB为病灶抑制蛋白,与较低WMH负荷和较好认知相关,是脑小血管病的候选治疗靶点。

研究设计与样本

  • Stage 1在神经影像亚组(n=5443)中测试候选蛋白与WMH体积的关联。
  • Stage 2使用双向孟德尔随机化、共定位和局部遗传相关性,基于血浆、血管和脑组织的顺式pQTL和cis-eQTL工具。
  • Stage 3对8例死后脑室周围白质样本(4例WMH病灶,4例对照)进行单核RNA测序。
  • Stage 4测试循环和遗传预测蛋白水平与一般认知能力的关联。

主要发现

  • Stage 1和2共同识别出CTSB和ECHDC3;较高血浆CTSB与较低WMH体积相关(β=-0.09 [95% CI, -0.13 to -0.05]; n=5260)。
  • 孟德尔随机化估计在所有5个工具集中方向一致(血浆pQTL β=-0.052 [95% CI, -0.064 to -0.040]),对白质微结构、血管周围间隙和腔隙性卒中有一致效应。
  • 单核RNA测序显示CTSB在病灶内下调,主要见于星形胶质细胞(log2fold change=-1.70)和少突胶质细胞(log2fold change=-0.48; both FDR P<1×10^-20)。
  • 较高血浆CTSB(β=0.061 [95% CI, 0.010–0.112]; n=5193)和cis pQTL多基因评分(β=0.031 [95% CI, 0.009–0.054]; n=8884)预测更好的认知表现。
  • ECHDC3除Stage 1外无一致关联。

临床怎么用

  • CTSB可能作为脑小血管病WMH负荷和认知障碍的潜在生物标志物或治疗靶点,但尚需临床验证。

局限性

  • 研究主要基于欧洲 ancestry 人群,外推性受限。
  • 单核RNA测序样本量小(8例),需更大样本验证。
  • ECHDC3未显示一致关联,CTSB的因果机制仍需实验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Ahead of Print. BACKGROUND:White matter hyperintensities (WMH) are a common brain magnetic resonance imaging marker of cerebral small vessel disease and a major risk factor for stroke and dementia, yet the molecular mechanisms governing lesion formation remain incompletely understood. We sought to identify circulating proteins that lie upstream of WMH and influence related clinical manifestations.METHODS:We conducted a 4-stage proteogenomic study. Stage 1 tested a WMH polygenic risk score against 2923 plasma proteins in 52 560 UK Biobank participants (mean age, 56.8 years, 53.9% female, 94.0% White), and candidate proteins against WMH volume in the neuroimaging subset (n=5443; mean age 54.2 years, 53.5% female). Stage 2 applied bidirectional Mendelian randomization, colocalization, and local genetic correlation using cis protein quantitative trait locus and cis expression quantitative trait locus instruments from plasma, vascular, and brain tissue. Stage 3 analyzed single-nucleus RNA sequencing of 8 postmortem periventricular white matter samples (4 WMH lesions, 4 controls; mean age, 81 years; 50% female). Stage 4 tested circulating and genetically predicted protein levels against general cognitive ability.RESULTS:Stages 1 and 2 converged on CTSB (cathepsin B) and ECHDC3 (enoyl-coenzyme A hydratase domain–containing 3). Higher plasma CTSB was associated with lower WMH volume (β=−0.09 [95% CI, −0.13 to −0.05]; n=5260), and Mendelian randomization estimates were directionally consistent across all 5 instrument sets (plasma protein quantitative trait locus β=−0.052 [95% CI, −0.064 to −0.040]), with concordant effects on white matter microstructure, perivascular spaces, and lacunar stroke. Single-nucleus RNA sequencing showed CTSB downregulation within lesions, predominantly in astrocytes (log2fold change=−1.70) and oligodendrocytes (log2fold change=−0.48; both false discovery rateP<1×10−20). Higher plasma CTSB (β=0.061 [95% CI, 0.010–0.112]; n=5193) and a cis protein quantitative trait locus polygenic score (β=0.031 [95% CI, 0.009–0.054]; n=8884) predicted better cognitive performance. ECHDC3 showed no consistent association beyond stage 1.CONCLUSIONS:Multimodal proteogenomic evidence nominates CTSB as a lesion-suppressed protein associated with lower WMH burden and better cognition, and a candidate therapeutic target for cerebral small vessel disease.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Multiomics Profiling Supports Cathepsin B as a Protective Factor in White Matter Hyperintensities and Cognition

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。